“Starting a rare-disease trial isn't going to move the needle one bit. Plus, you'll have biocheckers complaining that Missling is mismanaging resources.’
You have a bad habit of putting words in my mouth.
If Anavex put another rare disease into trials I would not say it was mismanaging resources. If fact, it’s quite the opposite. The real issue is credibility, i.e. doing what you tell investors you’re going to do.
Over the years I’ve advocated for a focus on rare diseases. As a reminder, years ago Missling talked about modeling Anavex on Alexion, which became hugely successful on a single rare disease. If fact, I’ve been critical of the strategy of chasing AD, which is the highest risk disease out there, as well as PDD. Missling was right when he said he would model Anavex on Alexion. Unfortunately, he went against his own strategy. I guess his ego was bigger than his good sense.
If you want to know what I think, ask me.
News 
Market Data 
Discover 
AI
